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Geron Corporation 
Calvin Harley now knows that he has 
little chance of curing cancer in mice. 
Whether he can do it in humans 
remains an open question. 
Harley is chief scientific officer of 
Geron Corporation (Menlo Park, 
California), a company formed in 1992 
to exploit the possible involvement of 
an enzyme called telomerase in 
cancer and aging. The simplicity and 
elegance of the telomerase theory has 
landed it on the cover of both Cell and 
Time, and in the pages of both Science 
and the Nm Yorker. 
But it is a theory that was initially 
based more on correlation than 
causation, and recent results in mice 
have left some researchers with 
doubts. Most are keeping an open 
mind, given the uncertain translation 
of mouse results to humans. “The 
arguments at this stage are purely 
theological,” says Elizabeth 
Blackburn of the University of 
California, San Francisco. “There is 
no scientific evidence, only opinion.” 
A theory is born 
Telomerase solves a problem first 
recognized by James Watson in 1972. 
The duplication of DNA is 
unidirectional, and it starts with an 
RNA primer. Even if a primer 
attaches to the very,end of a 
chromosome (the telomere), primer 
removal makes the new chromosome 
a little bit shorter. Telomerase 
corrects this erosion by making more 
copies of the protective sequence at 
the end of the chromosome 
(Figure 1). Telomerase has both an 
RNA component, which provides the 
template for catalysis, and a recently 
discovered protein component with 
reverse-transcriptase motifs. 
In germ cells, telomerase actively 
maintains the ends of chromosomes. 
But in most other cells telomerase is 
turned off. The telomeres shorten, 
until eventually the cells stop 
dividing. This fact, correlation 
number one, suggests that shortened 
telomeres might signal the cell to 
become senescent, a stable state in 
which the cell remains metabolically 
active but no longer divides. 
Senescent cells accumulate as 
organisms age, and their altered gene 
expression may contribute to various 
age-related diseases. 
The last thing that cancerous cells 
want to do is to senesce, and sure 
enough they reactivate telomerase 
activity (by a mechanism that remains 
unknown) and maintain the length of 
their telomeres. The finding that 
-85% of malignant cancer biopsies are 
positive for telomerase, correlation 
number two, has encouraged Geron to 
search for specific inhibitors of 
telomerase as cancer therapeutics. 
The mouse that kept on roaring 
To test the outcome of telomerase 
inhibition, Maria Blasco of the 
Universad Autonoma Madrid, and 
Carol Greider of Johns Hopkins 
University made knockout mice 
lacking the gene for telomerase RNA. 
Perhaps because of the long 
telomeres that they are born with, the 
mice live for as long as their parents 
and can generate cancer-causing cells. 
The knockout mice lose telomeric 
DNA at the rate of -4.8 kb per 
generation. By the sixth generation 
without telomerase, 56% of cells 
derived from the mice have the wrong 
numbers of chromosomes, 5% have 
undetectable amounts of telomeric 
repeats at one or more chromosome 
ends, and the average length of 
telomeric repeats has shrunk from 
-44 kb to -14 kb. Bad things, one 
suspects, are just around the corner. 
But in Blasco and Greider’s 
current description of the sixth 
generation, they find little evidence 
of telomerase’s importance in cancer 
and senescence. 
Their first test was growth in 
culture. Cultured human cells must 
jump over two barriers to avoid 
senescence and become immortal. 
Figure 1 
Mouse chromosomes stained for telomeric 
repeat DNA. Image courtesy of Geron. 
The first involves mutation of an 
oncogene or tumor suppressor to 
allow unregulated growth. This is 
enough to keep them going for a 
while, but then the telomeres shorten 
and cells enter a state called crisis. 
The cells that get through crisis have 
increased levels of telomerase. 
Mouse cells have a single period 
of slowdown which may be 
equivalent to crisis. The mouse cells 
lacking telomerase were just as 
efficient as normal cells at getting 
through this block, so it seems that 
re-expression of telomerase is not a 
critical event in this mouse version of 
in vi,itf-0 immortalization. 
For the z?z viva test, Blasco and 
Greider added oncogenes to cells 
cultured from sixth generation mice, 
then injected the cells into 
immunodeficient (nude) mice. 
Although these cells had divided over 
300 times without telomerase, they 
were still capable of forming tumors. 
Greider is concerned that the 
association of telomerase with some 
cancers could be just correlation. 
Last year Titia DeLange of 
Rockefeller University in New York 
reported that telomerase levels 
increased even in those cancerous 
mouse cells that still had long 
telomeres. “Just because a tumor 
expresses telomerase,” says Greider, 
“that doesn’t mean it needs it.” 
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Hope for humans (and Geron) 
Harley cites results from yeast 
(telomerase inhibition causes 
senescence) and cultured human 
cells (telomerase antisense causes 
crisis) as a counter to Greider’s 
findings. And he is not deterred by 
the mouse results. “The initial 
generations of mice are not a good 
model for telomerase biology in 
humans,” he says. Humans start off 
with many fewer telomeric repeats 
than mice, and some of the cancers 
that Geron hopes to treat have 
particularly diminutive telomeres. 
“I never thought that the telomerase 
approach was going to be a universal 
cure for all cancers,” says Greider. 
“I think there will be some specific 
cancers that will be good targets.” 
One of the worst-kept secrets in 
molecular biology is that mice 
beyond the sixth generation have 
significant problems, but until this 
work is published none of the authors 
are discussing it. These later 
generations of mice may vindicate 
parts of the telomere hypothesis, but 
they also raise the question of how 
long a telomerase inhibitor will take 
to start working. Harley has always 
acknowledged that there will be a lag, 
a time in which the existing telomere 
is gradually eaten away even as the 
cancer grows. He estimates the delay 
in human cells to be 20 population 
doublings, equivalent in theory to a 
million-fold increase in cell number. 
But Harley has calculated that, with 
the extensive cell death that is 
common in tumors, the tumor mass 
will increase by only several-fold. 
This is a disadvantage that Geron 
claims it can manage. “Every cancer 
therapy on the market today has a 
limitation,” says Harley. “We didn’t 
expect telomerase inhibitors to be 
any different-we don’t expect 
them to be a magic bullet. But we do 
expect them to be more universal 
and safer than current therapies.” 
Harley plans to use telomerase 
inhibitors to prevent metastases and 
relapses that start from just a few 
cells, not as treatments for large 
primary tumors. 
Another uncertainty involves a 
poorly characterized pathway named 
alternative lengthening of telomeres 
(ALT). Roger Reddel of the 
Children’s Medical Research 
Institute in Sydney has described 
this pathway in cultured cells that 
lack detectable telomerase activity 
but acquire long telomeres. As in 
yeast, this lengthening may work by 
non-reciprocal recombination 
between telomeric repeats, in which 
DNA is copied from one telomere to 
another. What is important ,for Geron 
is how often ALT happens in viva in 
humans. With this and other issues 
unresolved, David Kipling of the 
University of Wales at Cardiff says 
that “treating real people with real 
tumors is the only true experiment.” 
Diagnostics 
Approximately half of Geron’s 
research is focussed on finding a 
telomerase inhibitor. A project with 
less glamour but arguably less risk is 
the investigation of telomerase 
activity as a marker for cancerous 
cells. In this field correlation is 
enough; even if telomerase activation 
is a passive bystander in tumor 
formation it can be a valuable marker. 
Telomerase is associated with 
over 80% of malignant tumors. Only 
14% of benign and premalignant 
growths, and 6% of tissues adjacent 
to tumors, test positive. Many of 
these ‘false positives’ may be true 
positives, as the telomerase activity 
assay is especially sensitive, capable 
of detecting from one to ten 
telomerase-positive cells. 
“Telomerase is here to stay,” says 
Jerry Shay of the University of Texas 
Southwestern. “It’s an extraordinarily 
important new marker.” 
Telomerase screening of easily 
available cells could replace invasive 
biopsies and tissue pathology as an 
indicator of tumorigenicity. The 
samples collected would include 
urine (bladder cancer), sputum (lung, 
and head and neck cancer), blood 
enriched for epithelial cells (various 
metastatic cancers) and nipple- 
aspirated fluid (breast cancer). 
What was old is new again 
The idea that telomerase is involved 
in cell senescence, itself only a small 
part of the aging process, somehow 
got translated into the idea that 
telomerase controls lifespan. “But 
that was never proposed by anyone,” 
says Greider. Although Geron has 
images of elderly but spry individuals 
sprinkled liberally through its 
promotional materials, Geron is not 
planning to stop people from aging. 
They are, however, looking at 
how the cells with shortened 
telomeres affect several age-related 
diseases. Geron researchers found 
that telomeres shorten twice as fast in 
endothelial cells lining arteries 
compared to those lining veins, 
probably because the turbulence in 
arteries causes higher cell turnover. 
Consistent with this, telomere loss 
rates are highest for the sections of 
arteries subject to the most 
turbulence. Accumulating senescent 
cells may then lead to atherosclerosis. 
Judith Campisi of the University 
of California, Berkeley, has found 
that senescent cells accumulate as 
skin ages. She can see senescent skin 
cells by staining for the enzyme 
J3-galactosidase at neutral pH (it is 
active in normal cells only at low pH). 
Senescent skin cells produce too little 
collagen and too much collagenase, 
and the combination may contribute 
to the fragility of aging skin. 
Geron is using the chips made by 
Synteni, Inc. (see Chemistry 43 Biology, 
4, 157-158) to search for more genes 
that are expressed differentially in 
senescent cells, and hopes to modify 
that expression with small molecules. 
These newer research directions 
may be good insurance if humans 
turn out to be as indifferent to the 
loss of telomerase as mice. 
Meanwhile, supporters like Shay are 
ready to test the inhibitors. “There’s 
an optimistic and a pessimistic way 
to spin any story,” he says. “But 
these trials will be done either way.” 
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